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BACKGROUND: Major prevention trials for Alzheimer’s disease (AD) are now focusing on multidomain lifestyle
interventions. However, the exact combination of behavioral factors related to AD pathology remains unclear. In 2
cohorts of cognitively unimpaired individuals at risk of AD, we examined which combinations of personality traits,
neuropsychiatric symptoms, and cognitive lifestyle (years of education or lifetime cognitive activity) related to the
pathological hallmarks of AD, amyloid-b, and tau deposits.
METHODS: A total of 115 older adults with a parental or multiple-sibling family history of sporadic AD (PREVENT-AD
[PRe-symptomatic EValuation of Experimental or Novel Treatments for AD] cohort) underwent amyloid and tau
positron emission tomography and answered several questionnaires related to behavioral attributes. Separately,
we studied 117 mutation carriers from the DIAN (Dominant Inherited Alzheimer Network) study group cohort with
amyloid positron emission tomography and behavioral data. Using partial least squares analysis, we identified
latent variables relating amyloid or tau pathology with combinations of personality traits, neuropsychiatric
symptoms, and cognitive lifestyle.
RESULTS: In PREVENT-AD, lower neuroticism, neuropsychiatric burden, and higher education were associated with
less amyloid deposition (p = .014). Lower neuroticism and neuropsychiatric features, along with higher measures of
openness and extraversion, were related to less tau deposition (p = .006). In DIAN, lower neuropsychiatric burden
and higher education were also associated with less amyloid (p = .005). The combination of these factors accounted
for up to 14% of AD pathology.
CONCLUSIONS: In the preclinical phase of both sporadic and autosomal dominant AD, multiple behavioral features
were associated with AD pathology. These results may suggest potential pathways by which multidomain in-
terventions might help delay AD onset or progression.
Keywords: Alzheimer’s, PET, Prevention, Reserve, Resistance, Risk factors
https://doi.org/10.1016/j.biopsych.2020.01.023Given the limited successes of pharmacological treatments
for Alzheimer’s disease (AD), attention has shifted toward
risk or protective factors that might prevent or postpone
disease onset (1,2). Estimates suggest that a multidomain
lifestyle intervention that achieved a 10% reduction in risk
factors could prevent more than a million cases worldwide
(3). The mechanisms that link protective factors and AD risk
are not well understood, but current notions of resilience
and resistance may be helpful (4). While “resilience” refers
to the preservation of cognitive abilities in the presence of
AD pathology, “resistance” refers to avoidance of theN: 0006-3223pathology in the first place (5,6). These concepts, which are
not mutually exclusive, have been tested in the sporadic
form of the disease, given the causative genetic mutation in
autosomal dominant AD (ADAD). Here, we describe in-
vestigations in both disease forms of the relationships be-
tween several personality and behavioral features
associated with AD risk and presence of AD pathology.
Such relationships, tested in asymptomatic individuals,
might suggest sources of resistance pathway, thereby
hinting at modifiable pathways to postpone manifestation of
brain pathology.ª 2020 Society of Biological Psychiatry. 1
Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journal
Behavioral Factors Association With AD Pathology
Biological
PsychiatryIn sporadic AD, as much as a third of AD risk appears to be
related to modifiable factors such as level of education,
depression, and cognitive or physical activity (1,7). Education
and midlife cognitive activity have been associated with lower
levels of pathology in the preclinical phase of the disease and
with increased resilience to pathology in later stages (8,9).
Neuropsychiatric symptoms like depression and apathy are
known to increase over the course of the disease (10–12).
While some such features are likely a consequence of the
disease, midlife neuropsychiatric symptoms have been asso-
ciated with increased AD risk in later life (13). Personality traits
like neuroticism and conscientiousness have also been asso-
ciated with cognitive decline and risk of sporadic AD (14,15).
Admittedly, personality traits may change as a consequence of
the disease process, but a recent study showed that person-
ality traits in adolescence—a time when AD pathology is
unlikely—are associated with incident dementia 54 years later
(16). Furthermore, personality traits usually remain stable in the
early stages of the disease (17).
Fewer studies have explored the associations between
behavioral/personality features and AD risk in ADAD. Higher
resilience has been noted in individuals having higher levels of
education, using the estimated years to symptom onset as a
proxy for disease severity (18). Less physical activity and lower
levels of education have also been associated with increased
AD pathology and cognitive decline in preclinical ADAD
(19–21). While personality has been studied less in ADAD,
neuropsychiatric symptoms such as depression and anxiety
have been found to remain stable in asymptomatic individuals
but to increase in individuals with cognitive impairment (22).
When compared with noncarriers, asymptomatic ADAD mu-
tation carriers have been found to exhibit fewer depressive
symptoms (22).
During the presymptomatic phase of either disease, in-
dividuals remain cognitively normal despite their accumulation
of AD pathological hallmarks, amyloid-b (Ab) and tau proteins
(23,24). This silent phase, which can span more than 2
decades, represents an ideal window of opportunity for
preventive strategies (25). Given the complex etiology of AD,
targeting multidomain factors is rapidly becoming the norm in
prevention trials (26). We therefore used multivariate analyses
to investigate combinations of personality traits, neuropsy-
chiatric symptoms, and cognitive lifestyle in relation to Ab and
tau deposition in cognitively normal older adults at increased
risk of sporadic or autosomal dominant forms of AD (mutation
carriers; for the latter, Ab only). We expected to find similar
associations in both disease forms, but perhaps weaker
associations in ADAD, given the latter’s overwhelming genetic
diathesis. We reasoned that discovery of such associations in
the asymptomatic phase of the disease could suggest that
preventive behavioral interventions may be useful in at-risk
persons that are still free from pathology.
METHODS AND MATERIALS
Participants
We studied 232 cognitively unimpaired participants, including
115 individuals at risk of sporadic AD from the PRe-
symptomatic EValuation of Experimental or Novel Treatments
for AD (PREVENT-AD) study and 117 asymptomatic individuals2 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalwith ADAD from the Dominant Inherited Alzheimer Network
(DIAN) study group. PREVENT-AD enrolls older adults having
intact cognition but a parent or 2 siblings diagnosed with
AD-like dementia, who are therefore at increased risk of spo-
radic AD (27). Participants were above 60 years of age, or
between 55 and 59 if their age was fewer than 15 years from
their parent’s age of symptom onset. Participants were free of
major neurological and psychiatric diseases at enrollment. In-
clusion criteria included intact cognition based on the Montreal
Cognitive Assessment (score above 25) (28) and a 45-minute
standardized neuropsychological evaluation using the
Repeatable Battery for the Assessment of Neuropsychological
Status (29). The cognitive status of individuals with question-
able neuropsychological status was reviewed in consensus
meetings of neuropsychologists (including SV) and/or psychi-
atrists (including JCSB). Only participants with Ab positron
emission tomography (PET), tau PET, and data on behavioral
factors were included, resulting in 115 participants (out of 324
active PREVENT-AD participants as of May 2019). The DIAN
study group enrolls individuals over 18 years old with a family
history of ADAD. We selected mutation carriers who were
cognitively normal as evidenced by Clinical Dementia Rating
(30) score of 0 and who had Ab PET and behavioral data
available. Those studied comprised 117 participants (85
PSEN1 mutation carriers, 17 PSEN2 mutation carriers, and 15
APP mutation carriers) out of 146 mutation carriers archived in
the DIAN data freeze of May 2016.
Behavioral Factors
All participants filled out questionnaires to assess various
behavioral factors plausibly related to AD risk (Supplemental
Table S1). For ease of interpretation, we grouped these fac-
tors into 3 categories: “Big Five” personality traits (neuroticism,
openness, extraversion, agreeableness, conscientiousness),
neuropsychiatric symptoms (depression, anxiety, stress,
apathy), and features of cognitive lifestyle (years of education,
lifetime cognitive activity). In PREVENT-AD, all questionnaires
were answered at home 6 months to a year before PET (mostly
electronically, but 10% responded by paper version). Follow-
up questionnaires were sent to participants every year or so,
resulting in 3 time points for neuropsychiatric symptoms (2016,
2017, 2018) and 2 for personality (2016 and 2018). Intraclass
correlation coefficients and their 95% confidence intervals,
based on absolute agreement in 2-way mixed-effects models,
were computed using SPSS, version 20 (IBM Corp., Armonk,
NY) (31). Supplemental Figures S1 and S2 display correlations
between these scores at the different time points.
In DIAN, all questionnaires were answered at the baseline
visit, which also included Ab PET. The DIAN personality
questionnaire (International Personality Item Pool Represen-
tation of the Revised NEO Personality Inventory [IPIP-NEO-
120]) (32) was more detailed than the Big Five Inventory used in
PREVENT-AD and yielded scores on 30 personality facets
along with the Big Five personality domains. The 30 facets
were used only in complementary analyses.
Image Acquisition
PREVENT-AD participants underwent PET using [18F]NAV4694
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Aβ or tau SUVR 
A B C Figure 1. Partial least squares analysis findsmaximally correlated linear combinations of two
input matrices, one with behavioral features (top
matrix in A) and the other with Alzheimer’s disease
pathology across defined cortical regions (bottom
matrix in A). These two matrices are then correlated
together, and this latter matrix (B) is decomposed
into multiple latent variables using singular value
decomposition. (C) An example of a latent variable.
Briefly, each latent variable consists of a singular
value (related to the covariance between the 2 input
matrices) and 2 vectors of weights representing how
much each behavioral feature and each brain region
contribute the overall multivariate relationship. Ab,
amyloid-b; SUVR, standardized uptake value ratio.
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Psychiatrytau deposition. DIAN participants underwent Ab PET only us-
ing Pittsburgh compound B ([11C]PIB). A T1-weighted struc-
tural image was also acquired using a similar magnetization
prepared rapid acquisition gradient-echo sequence in both
studies (greater detail available in the Supplement).
Image Processing
Both PREVENT-AD and DIAN scans were processed locally
using the same pipeline (see https://github.com/villeneuvelab/
vlpp for more details and the Supplement for parameters
used). Ab and tau PET images were registered to the T1-
weighted scan of each participant, which had been
segmented with the Desikan-Killiany atlas using FreeSurfer
version 5.3 (33). Images were then masked to remove the scalp
and cerebrospinal fluid, to reduce contamination by non–gray
and non–white matter voxels. In PREVENT-AD, PET images
were smoothed with a Gaussian kernel of 6 mm. Standardized
uptake value ratios (SUVRs) were obtained using the whole
cerebellum as reference region for Ab PET (34) and the inferior
cerebellar gray matter for tau PET (35). DIAN PET images were
smoothed with a Gaussian kernel of 8 mm to diminish multisite
effect (36), and Ab PET SUVRs were obtained using the whole
cerebellum as reference region. Mean SUVR from the left and
right hemispheres in each Desikan-Killiany region was used for
further analyses. The frontal pole region was excluded owing
to weaker registration to the structural scan. Only a subset of
sensitive regions was included for each modality in the ana-
lyses. For Ab, bilateral SUVRs in the lateral and medial pre-
frontal, parietal, lateral temporal, and cingulate cortical regions
were included in multivariate analyses because these are key
regions of Ab deposit in the preclinical and clinical phases of
AD (37,38). The weighted average across all these regions is
referred to here as global Ab index SUVR (38,39) and used in
univariate analyses. For tau PET, bilateral SUVRs in the regions
of Braak stages I (entorhinal cortex), III, and IV were included in
the multivariate analysis since those stages capture regions upB
to early tau accumulation (40,41) (Supplemental Table S2).
Average SUVR in separate Braak stages was also computed
and used in univariate analyses. Braak stage II (hippocampus)
was excluded, however, owing to signal contamination from
the choroid plexus (42), and regions of Braak stages V and VI
were also excluded, given that they represent later stages of
AD progression (43,44).
Statistical Analyses
Univariate Analyses. We first estimated univariate para-
metric correlations between each individual behavioral feature
and pathology. We used global Ab index SUVR in both
PREVENT-AD and DIAN. Tau SUVR in Braak stages I, III, and
IV was used in PREVENT-AD. Also, to evaluate the extent to
which behavioral features were related to one another, we
calculated the parametric correlation between all factors. We
considered p values , .05 significant. Associations surviving
false discovery rate (FDR) of 5% are also reported to account
for multiple comparisons.
Multivariate Analyses. The main statistical approach was
partial least squares (PLS) analysis (45,46), implemented using
PLS Software v6.15.1 (https://www.rotman-baycrest.on.ca/
index.php?section&equals;84) on MATLAB (The MathWorks,
Inc., Natick, MA) v2016a. This approach allowed investigation
of relationships between combinations of behavioral factors
and AD pathology across the brain. PREVENT-AD permitted
2 PLS analyses, relating these behavioral features with Ab and
tau independently. Two PLS analyses were also performed
in DIAN: the primary analysis relating similar behavioral
features with Ab and a complementary one further detailing
personality after including the 30 personality facets available
exclusively in DIAN.
Figure 1 explains these analyses (greater detail is available
in the Supplement). Briefly, PLS finds linear combinations of 2
sets of variables (organized in 2 matrices) that correlateiological Psychiatry - -, 2020; -:-–- www.sobp.org/journal 3
Table 1. Participants’ Demographics and Behavioral Features
Demographics and Behavioral Features PREVENT-AD (n = 115) DIAN (n = 117)
Age, Years 67.6 6 5.0 (58.6 to 83.3) 34.6 6 9.4 (18.0 to 61.0)
Estimated Years to Onseta 25.7 6 7.8 (220.8 to 16.8) 212.9 6 8.0 (231.5 to 11.8)
Gender, F:M, n (%F) 86:29 (75%) 64:53 (55%)
APOE ε4 Carriers, n (%) 44 (38%) 36 (31%)
Global Ab SUVRb 1.1 6 0.3 (0.9 to 2.3) 0.9 6 0.2 (0.8 to 1.6)
Tau Braak I SUVR 1.1 6 0.1 (0.7 to 1.7) –
Tau Braak III SUVR 1.2 6 0.1 (0.8 to 1.7) –
Tau Braak IV SUVR 1.1 6 0.1 (0.9 to 1.6) –
MMSE 28.8 6 1.3 (24 to 30) 29.1 6 1.2 (24 to 30)
Cognitive Lifestyle
Education, years 15.0 6 3.2 (7.0 to 22.0) 15.2 6 3.0 (10.0 to 24.0)
Lifetime cognitive activity 2.6 6 0.7 (1.2 to 4.4) –
Neuropsychiatric Symptoms
Depression 1.3 6 1.9 (0 to 10.0) 1.5 6 1.8 (0 to 9.0)
Anxiety 2.1 6 3.6 (0 to 18.0) –
Stress 4.7 6 5.2 (0 to 24.0) –
Apathy 27.8 6 6.2 (18.0 to 46.0) –
NPI-Q – 0.7 6 1.8 (0 to 11.0)
Personalityc
Openness 38.9 6 6.5 (21.0 to 50.0) 79.5 6 11.8 (49.0 to 107.0)
Neuroticism 17.6 6 6.1 (8.0 to 35.0) 60.1 6 13.8 (31.0 to 94.0)
Conscientiousness 37.4 6 5.4 (19.0 to 45.0) 96.0 6 12.3 (67.0 to 120.0)
Agreeableness 39.2 6 4.0 (26.0 to 45.0) 95.8 6 10.2 (62.0 to 115.0)
Extraversion 26.7 6 5.6 (14.0 to 40.0) 85.6 6 12.1 (47.0 to 109.0)
Data presented as mean 6 SD (range) unless noted otherwise.
Ab, amyloid-b; DIAN, Dominant Inherited Alzheimer Network; F, female; M, male; MMSE, Mini-Mental State Evaluation; NPI-Q, Neuropsychiatric
Inventory Questionnaire; PREVENT-AD, PRe-symptomatic EValuation of Experimental or Novel Treatments for AD; SUVR, standardized uptake
value ratio.
aFor PREVENT-AD participants, data are sporadic estimated years to onset (data available for 111 participants). For DIAN participants, data are
estimated years to onset (age of participant 2 age of the parent at symptom onset).
b[18F]NAV4694 is used in PREVENT-AD and [11C]PIB is used in DIAN.
cPersonality traits are assessed with the Big Five Inventory in PREVENT-AD and the International Personality Item Pool Representation of the
Revised NEO Personality Inventory in DIAN, and the 2 questionnaires have different scales.
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Psychiatrymaximally with each other. The first matrix enters the behav-
ioral factors in columns with entries corresponding to the score
on the various questionnaires; the rows correspond to indi-
vidual participants. The behavioral data were z scored col-
umnwise since all questionnaires were on different scales. The
second matrix contains either regional Ab or tau SUVR in
columns and rows corresponding to participants. The output
from the PLS analyses are sets of latent variables relating
behavioral features and AD pathology. The number of latent
variables is equal to the smallest dimension of the matrices,
here the number of behavioral factors. Permutation tests were
used to identify which latent variables were significant, with p
value , .05 being considered significant. The latent variables
are a triplet of 1) a singular value, 2) a vector of weights
attributed to each behavioral factor, and 3) a vector of weights
attributed to the various cortical regions. In the significant
latent variable(s), bootstrap resampling was used to identify
the most stable features and brain regions contributing to the
behavioral factors–pathology relationship. Lastly, the vectors
of weights from each behavioral factor and each brain region
were multiplied by the original data of each participant. These 2
values correspond to each participant’s weighted score of
behavioral factors and weighted score of pathology.4 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalCorrelating these 2 scores across participants provided an
estimate of the strength of the multivariate relationship be-
tween the behavioral and pathology features.
Complementary Analyses. One complementary question
is whether behavioral factors influence AD pathology,
pathology influences behavioral factors, or these relationships
are bidirectional. This question is particularly relevant for
neuropsychiatric symptoms, inasmuch as education level and
lifetime cognitive activity typically precede AD pathology and
personality traits generally remain stable over time, even in
individuals with AD-related cognitive impairment (15). Longi-
tudinal PET scans will be needed to address this question
more fully. Nonetheless, we sought to take advantage of
3-year follow-up for neuropsychiatric symptoms and evalu-
atedwhether Ab (global Ab indexSUVR) and tau (entorhinal tau
SUVR) were associated with change in neuropsychiatric
symptom scores. To do this, we used linear mixed-effects
models having random slope and intercept, in which a time-
by-Ab or time-by-tau SUVR interaction predicted longitudinal
neuropsychiatric symptom scores. These mixed-effects

















































































































































































Cognitive lifestyle           
Neuropsychiatric symptoms
Personality traits
Figure 2. Correlations between behavioral features in both cohorts. Intercorrelation (Pearson correlation) between behavioral factors in PRe-symptomatic
EValuation of Experimental or Novel Treatments for AD (PREVENT-AD) (A) and Dominant Inherited Alzheimer Network (DIAN) (B) study groups. White stars
correspond to negative correlations and black stars to positive correlations that remained significant after false discovery rate correction. NPI-Q, Neuro-
psychiatric Inventory Questionnaire.
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Sample characteristics are detailed in Table 1. Information on
cognitive data in both cohorts is available in Supplemental
Tables S3 and S4.
Univariate Relationship Between Behavioral
Features and Ab and Tau
In PREVENT-AD, only neuroticism was related the global Ab
index SUVR, with higher scores on neuroticism related with
higher Ab deposition (R = .21, p = .02, but does not survive
FDR correction; Supplemental Table S5). Tau SUVR in Braak I
(entorhinal cortex) was related with different behavioral
features (personality traits, apathy, and lifetime cognitive
activity [R = .21–.34, p , .001–.02]), while only lifetime cogni-
tive activity was related to tau SUVR in Braak III or IV
(Supplemental Table S5). All associations with tau SUVR in
Braak I survived FDR correction.
In DIAN, fewer behavioral features were available for
analyses (8 rather than 11), and some of the questionnaires
differed from those in PREVENT-AD (Supplemental Table S1).
Higher level of education correlated with lower global Ab index
(R = 2.19, p = .04, but does not survive FDR correction;
Supplemental Table S5). Of note, mutation type had virtually
no effect on behavioral features (the only difference being that
PSEN2 mutation carriers had lower extraversion scores than
PSEN1 carriers in post hoc testing, p = .04). There was also no
difference on any behavioral features between asymptomatic
mutation carriers and 127 noncarriers.
Intercorrelation Among Behavioral Features
Intercorrelations among behavioral features revealed associ-
ations between about half of the features in PREVENT-ADB
(Figure 2A). The neuropsychiatric symptoms were themselves
intercorrelated, and neuropsychiatric symptoms were (unsur-
prisingly) associated mainly with higher neuroticism and lower
extraversion. Furthermore, education, cognitive activity, and
openness were positively correlated with one another. In DIAN,
more years of education was also associated with increased
openness, and intercorrelations were found between different
personality traits (Figure 2B). These numerous intercorrelations
suggest that a wide variety of behavioral features relate to one
another, thus justifying our decision to investigate them in
combination.
Relationship of AD Pathology With Multidomain
Behavioral Features
In PREVENT-AD there was one significant latent variable
relating behavioral features with Ab (p = .014, 95% of the PLS
variance being explained by this variable). Figure 3A displays
the different weights of the behavioral features and brain
regions that form this latent variable. A combination of lower
neuroticism, anxiety, and apathy along with higher education
and openness were the features that were most strongly
associated with lower Ab burden. All regions of the global Ab
index contributed to the relationship. The correlation between
the weighted scores of the behavioral features and of regional
Ab pathology across participants was R = .23, p = .013,
accounting for 5.3% of the Ab variance.
The multivariate analysis with tau also revealed one latent
variable relating behavioral features with regional tau SUVR
(p = .006, 82% of the PLS variance was explained by this
variable). Figure 3B displays the different weights of the
behavioral features and brain regions forming this latent vari-
able. Almost all behavioral variables contributed to thisiological Psychiatry - -, 2020; -:-–- www.sobp.org/journal 5
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Figure 3. Latent variables from partial least squares analysis relating behavioral features and Alzheimer's disease (AD) pathology in both cohorts. Results
from the different partial least squares analyses representing which combinations of behavioral features relate to amyloid-b (Ab) pathology in PRe-symptomatic
EValuation of Experimental or Novel Treatments for AD (PREVENT-AD) study group (A), tau pathology in PREVENT-AD study group (B), and Ab pathology in
Dominant Inherited Alzheimer Network (DIAN) study group (C). Bar graphs represent the weight of each behavioral feature to the multivariate relationship.
Confidence intervals are derived from bootstrap resampling. All brain regions included in the partial least squares analyses are projected on the brains.
Bootstrap ratios correspond to the importance of each region to the behavioral feature-pathology relationship. NPI-Q, Neuropsychiatric Inventory
Questionnaire.
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Psychiatryrelationship, with a combination of higher scores on openness
and extraversion, higher cognitive activity, lower neuropsy-
chiatric symptoms, and neuroticism being related to less tau
burden. The top region related to behavioral features was the
entorhinal cortex (Braak I), followed by others in the medial and
lateral temporal lobe. Regions outside the temporal lobe did
not contribute, which is in keeping with the known deposition
pattern of tau in the asymptomatic phase of AD (40,47). The
correlation between the weighted scores of the behavioral
features and regional tau pathology across participants was
R = .29, p = .002, accounting for 8.4% of variance explained.
In DIAN, one latent variable related behavioral features with
Ab (p = .005, 91% of the PLS variance explained; Figure 3C).
More years of education and a lower score on the Neuropsy-
chiatric Inventory Questionnaire were the factors that related
most strongly to lower Ab burden. All regions included in the
global Ab index contributed to this relationship. The correlation
between weighted scores of the behavioral features and
regional Ab pathology across participants was R = .26,
p = .005, accounting for 6.7% of variance explained. To obtain
a more fine-grained picture of these associations in DIAN, the
PLS was repeated, substituting the Big Five personality traits
with the 30 personality facets. Again, one latent variable
(p = .004, 88% of PLS variance explained) related behavioral
features and Ab. Higher intellect (a facet of the openness trait),
along with more years of education and a low score on
Neuropsychiatric Inventory Questionnaire, were related to
lower Ab burden (Figure 4). The correlation between the6 Biological Psychiatry - -, 2020; -:-–- www.sobp.org/journalweighted scores of the behavioral features and pathology was
R = .37, p , .001, accounting for 14% of the variance.
Stability Over Time of Behavioral Features in
PREVENT-AD
All analyses presented thus far included the behavioral feature
assessments nearest in time to the PET scans. We also
evaluated the stability of such self-reported questionnaire
responses, taking advantage of the longitudinal assessment of
3 years for neuropsychiatric symptoms and 2 years for per-
sonality (Supplemental Figures S1 and S2). Education and
lifetime cognitive activity were only assessed once as they are
typically fixed. Overall, there was moderate stability of neuro-
psychiatric symptoms over 3 years (intraclass correlation
coefficient between 0.55 and 0.73; Supplemental Figure S1)
and, predictably, better stability of personality traits over 2
years (intraclass correlation coefficient between 0.76 and 0.81;
Supplemental Figure S2). Using the 3-year data available on
neuropsychiatric symptoms, we also found no apparent influ-
ence of the level of Ab or tau on change of neuropsychiatric
symptoms over time (Supplemental Table S6; only the
relationship of tau and stress had a p value of .03, but this did
not survive correction for multiple comparisons).
DISCUSSION
It has been estimated that up to 35% of AD risk is modifiable by
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Figure 4. Latent variable from partial least squares analysis relating
personality facets and behavioral features with amyloid-b (Ab) in Dominant
Inherited Alzheimer Network (DIAN) study group. Result from the partial least
squares analysis relating behavioral features including the 30 personality
facets and Ab pathology across brain regions in DIAN. Bar graphs represent
the weight of each behavioral feature to the multivariate relationship. Con-
fidence intervals are derived from bootstrap resampling. All brain regions
included in the analysis are projected on the brain. Bootstrap ratios corre-
spond to the importance of each region to the behavioral feature-pathology
relationship. GDS, Geriatric Depression Scale; NPI-Q, Neuropsychiatric In-
ventory Questionnaire.
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Beyond these factors, facets of personality, such as neuroticism
(15), and other behaviors, such as sleep dysregulation (48), have
also been associatedwith a risk of AD, suggesting that evenmore
than 35% of AD risk may be modifiable. Working in the asymp-
tomatic stage of the sporadic and autosomal dominant forms of
AD, we tested whether combinations of multidomain behav-
ioral features were related to AD pathology and to what
extent. In cognitively unimpaired late-middle-aged in-
dividuals at increased risk of sporadic AD, several combi-
nations of factors encompassing personality traits,
neuropsychiatric symptoms, and cognitive lifestyle were
related to Ab and tau deposition in the brain. In asymp-
tomatic ADAD mutation carriers, education and psychiatric
symptoms were related to Ab. Across analyses, the variance
explained from behavioral feature–pathology relationships
ranged from 5% to 14%. Although this might appearB
modest, reduction of AD risk factors by such percentages
could have a major impact on future disease prevalence,
preventing millions of cases (3).
In sporadic AD, personality traits had been described pre-
viously as being related to the incidence of dementia (14,15).
Little was known, however, about associations with Ab and tau
pathology in the earliest phases of the disease (49,50). In
PREVENT-AD, a higher score on neuroticism was among the
key factors related to the presence of both pathologies. Our
results are in accord with the aforementioned studies in which
neuroticism, characterized by negative emotions (51), is the
dominating trait associated with increased risk of AD. Neuro-
psychiatric symptoms—which are correlated with
neuroticism—were also associated with Ab and tau burden.
Other personality traits such as openness and extraversion
also related to tau pathology in both univariate and multivariate
analyses.
Our results add to an abundant literature reporting
increased prevalence of neuropsychiatric symptoms with dis-
ease progression (52–55) and suggest that neuropsychiatric
features may be related to pathology even in cognitively
normal individuals (56–58). Given that our findings are only
correlational and that pathology accumulates over many years,
reverse causality is also possible (i.e., that pathology has
already affected the magnitude of neuropsychiatric symptoms
even in cognitively unimpaired individuals). Neuropsychiatric
symptoms are frequent in individuals with dementia (52,55),
and at that late disease stage they are most certainly a
consequence of the disease. Longer follow-up and longitudinal
PET scans will be needed to clarify which behavioral features
cause, and which are a consequence of, AD pathology. By
contrast, given that personality traits are abiding characteris-
tics of an individual, we postulate that they are probably true
risk factors of the disease. Clarifying such relationships might
help target the right factors at the optimal time for prevention.
In DIAN mutation carriers, the main factors related to Ab
deposition were fewer years of education, lower scores on the
intellect personality facet, and higher neuropsychiatric symp-
tom burden. Here, personality traits did not appear to be
driving factors related to the pathology. The importance of
personality traits in sporadic AD might be due to a lifelong
effect of personality, which influences lifestyle choices and
how one copes with situations throughout life, eventually
affecting pathology accumulation in old age. DIAN mutation
carriers, being much younger, may not exhibit such an effect of
personality traits on Ab burden. This idea remains in line with
recent studies suggesting the influence of lifestyle factors such
as physical activity and education on (later) AD progression in
the presence of a fully penetrant genetic mutation (19).
Perhaps importantly, the current work assesses multiple
behavioral features in the same analytic design. As shown in
Figure 2, many behavioral features are, in fact, highly corre-
lated. The net sum of these factors, rather than one factor
alone, may therefore be associated with an altered risk of
developing AD pathology. We included protective factors that
might contribute to higher cognitive reserve or brain mainte-
nance (4,59) but also risk factors that might contribute to
cognitive debt. The concept of cognitive debt refers to the
constellation of behaviors (mainly stress and neuropsychiatric
symptoms) that increase individual risk to AD (60). Asiological Psychiatry - -, 2020; -:-–- www.sobp.org/journal 7
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Psychiatrypostulated by this hypothesis, lower neuroticism and neuro-
psychiatric symptoms might be a way to reduce vulnerability to
Alzheimer’s dementia. Along with high cognitive reserve,
modulating these risk factors might be important targets to
resist pathology accumulation.
Other important limitations of this study include relatively
modest sample sizes in the 2 samples. It will be important to test
whether such findings generalize to populations without the
added risk conferred by a family history of AD. Most participants
were also highly educated, and it will be of interest to know
which associations would still be found in individuals with less
education. For example, certain associations between high
school personality traits and dementia in late life have been re-
ported as being stronger in individuals with higher socioeco-
nomic status (16). Also, associations with openness (or intellect)
and education could reflect an underlying relationship with
different intelligence measurements (61,62), which, unfortu-
nately, were not available in either cohort. Furthermore, in
PREVENT-AD, behavioral and PET data were not collected at
the same time. We did, however, show that the self-reported
behavioral features had good stability over 2 to 3 years.
Given the failures of many clinical trials, new avenues are
needed to prevent or slow AD progression. Multidomain life-
style interventions have shown some promises in delaying
cognitive decline. We suggest here that such interventions
might also postpone accumulation of AD pathology in both
sporadic and autosomal dominant forms of AD. In the former,
behavioral interventions might focus on aspects of personality
and/or emotional regulation, as those features were strongly
related to both Ab and tau deposition. Beyond this, acting on
personality traits could have a positive impact on lifestyle
changes (63). While more work is needed to understand the
mechanisms by which behavioral features may influence AD
risk, our results may suggest that personality, neuropsychiatric
symptoms, and lifestyle features should be considered when
assessing multidomain interventions to postpone the accu-
mulation of AD pathology and its related clinical expression.ACKNOWLEDGMENTS AND DISCLOSURES
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